Actinogen Medical Limited (AU:ACW) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Actinogen Medical Limited is making strides in its Alzheimer’s and depression drug trials, with the XanaMIA trial expanding in the US and Australia and positive results from its XanaCIDD trial on depression. The company has also bolstered its leadership by appointing Andrew Udell as Chief Commercial Officer, highlighting its commitment to advancing late-stage clinical developments. Financially, Actinogen announced a successful $11.1 million capital raising to support its ongoing projects.
For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.